Molecular basis for the treatment of renal cell carcinoma

Cristina Suárez; Rafael Morales; Eva Muñoz; Jordi Rodón; Claudia M. Valverde; Joan Carles

doi:10.1007/s12094-010-0461-4

Molecular basis for the treatment of renal cell carcinoma

Cristina Suárez, Rafael Morales, Eva Muñoz, Jordi Rodón, Claudia M. Valverde, Joan Carles

Research output: Contribution to journal › Review article › peer-review

15 Scopus citations

Abstract

Renal cell carcinoma (RCC) is a heterogeneous malignancy whose incidence rate has notably increased in recent years without any evident reason. Traditionally, RCC has been resistant to classic treatments (chemotherapy, radiotherapy and hormonal therapy), with only a small percentage of patients benefiting from cytokine therapy. Different hereditary syndromes have been associated with RCC, Von Hippel Lindau (VHL) being the most important syndrome. Understanding key molecular pathways implicated in the tumorigenesis of RCC has crystallised in the development of more effective therapies. Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.

Original language	English (US)
Pages (from-to)	15-21
Number of pages	7
Journal	Clinical and Translational Oncology
Volume	12
Issue number	1
DOIs	https://doi.org/10.1007/s12094-010-0461-4
State	Published - Jan 2010
Externally published	Yes

Keywords

Key pathways
Molecular basis
Renal cell carcinoma
Targeted therapies

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1007/s12094-010-0461-4

Cite this

@article{176a35aa0713476e9eceee704c09838e,

title = "Molecular basis for the treatment of renal cell carcinoma",

abstract = "Renal cell carcinoma (RCC) is a heterogeneous malignancy whose incidence rate has notably increased in recent years without any evident reason. Traditionally, RCC has been resistant to classic treatments (chemotherapy, radiotherapy and hormonal therapy), with only a small percentage of patients benefiting from cytokine therapy. Different hereditary syndromes have been associated with RCC, Von Hippel Lindau (VHL) being the most important syndrome. Understanding key molecular pathways implicated in the tumorigenesis of RCC has crystallised in the development of more effective therapies. Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.",

keywords = "Key pathways, Molecular basis, Renal cell carcinoma, Targeted therapies",

author = "Cristina Su{\'a}rez and Rafael Morales and Eva Mu{\~n}oz and Jordi Rod{\'o}n and Valverde, {Claudia M.} and Joan Carles",

year = "2010",

month = jan,

doi = "10.1007/s12094-010-0461-4",

language = "English (US)",

volume = "12",

pages = "15--21",

journal = "Clinical and Translational Oncology",

issn = "1699-048X",

publisher = "Springer-Verlag Italia",

number = "1",

}

TY - JOUR

T1 - Molecular basis for the treatment of renal cell carcinoma

AU - Suárez, Cristina

AU - Morales, Rafael

AU - Muñoz, Eva

AU - Rodón, Jordi

AU - Valverde, Claudia M.

AU - Carles, Joan

PY - 2010/1

Y1 - 2010/1

N2 - Renal cell carcinoma (RCC) is a heterogeneous malignancy whose incidence rate has notably increased in recent years without any evident reason. Traditionally, RCC has been resistant to classic treatments (chemotherapy, radiotherapy and hormonal therapy), with only a small percentage of patients benefiting from cytokine therapy. Different hereditary syndromes have been associated with RCC, Von Hippel Lindau (VHL) being the most important syndrome. Understanding key molecular pathways implicated in the tumorigenesis of RCC has crystallised in the development of more effective therapies. Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.

AB - Renal cell carcinoma (RCC) is a heterogeneous malignancy whose incidence rate has notably increased in recent years without any evident reason. Traditionally, RCC has been resistant to classic treatments (chemotherapy, radiotherapy and hormonal therapy), with only a small percentage of patients benefiting from cytokine therapy. Different hereditary syndromes have been associated with RCC, Von Hippel Lindau (VHL) being the most important syndrome. Understanding key molecular pathways implicated in the tumorigenesis of RCC has crystallised in the development of more effective therapies. Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.

KW - Key pathways

KW - Molecular basis

KW - Renal cell carcinoma

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=76049123926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76049123926&partnerID=8YFLogxK

U2 - 10.1007/s12094-010-0461-4

DO - 10.1007/s12094-010-0461-4

M3 - Review article

C2 - 20080466

AN - SCOPUS:76049123926

SN - 1699-048X

VL - 12

SP - 15

EP - 21

JO - Clinical and Translational Oncology

JF - Clinical and Translational Oncology

IS - 1

ER -

Molecular basis for the treatment of renal cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this